Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Miguel Hernández-Bronchud"'
Autor:
Miguel Hernández-Bronchud, Antonio Guilabert-Vidal, Carlos Muñoz-Santos, Joaquin Sola-Ortigosa
Publikováno v:
Scientia
Adenocarcinoma apocrino cutáneo; Enfermedad de Paget extramamaria; Tratamiento Adenocarcinoma apocri cutani; Malaltia de Paget extramamària; Tractament Cutaneous apocrine adenocarcinoma; Extramammary Paget's disease; Treatment El carcinoma apocrino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdb5bc30e95041948834dd71c8e360c5
https://doi.org/10.1016/j.ad.2021.04.010
https://doi.org/10.1016/j.ad.2021.04.010
Autor:
Miguel Hernández-Bronchud
Publikováno v:
Journal of Clinical and Medical Research.
Placentation arose in mammalian evolution some 150-200 M years ago and integrates in a rather ingenious manner a large number of previously evolved multicellular regulatory pathways which include: angiogenesis, inflammatory cytokines and interleukins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51a1c5807ce5beb7ce493e07976624ab
https://doi.org/10.37191/mapsci-2582-4333-4(5)-123
https://doi.org/10.37191/mapsci-2582-4333-4(5)-123
Autor:
Miguel Hernández-Bronchud
Publikováno v:
Journal of Science, Humanities and Arts - JOSHA. 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca92b3e27d8b095f193ce9e201585572
https://doi.org/10.17160/josha.7.3.677
https://doi.org/10.17160/josha.7.3.677
Autor:
Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Cornelius F. Waller
Publikováno v:
Breast, Vol 58, Iss , Pp 18-26 (2021)
Background: Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast c
Externí odkaz:
https://doaj.org/article/398ce9856ea34116bdedd35208f23846